Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine in Advanced Hepatocarcinoma
2008-002299-92Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in hepatocellular carcinoma (HCC), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Time to progression. Started Jul 2008; status: completed.
02
Drugs
capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-002299-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002299-92.